scholarly journals Improving the Diagnosis and Management of Neuroendocrine Tumors: Utilizing New Advances in Biomarker and Molecular Imaging Science

2013 ◽  
Vol 98 (1) ◽  
pp. 16-30 ◽  
Author(s):  
Valeria Giandomenico ◽  
Irvin M. Modlin ◽  
Fredrik Pontén ◽  
Mats Nilsson ◽  
Ulf Landegren ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Neuroendocrine Tumors ◽  
Diagnosis And Management ◽  
Imaging Science

scholarly journals Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors

2020 ◽  
Vol 9 (11) ◽  
pp. 3679
Author(s):  
Anna Yordanova ◽  
Hans-Jürgen Biersack ◽  
Hojjat Ahmadzadehfar
Keyword(s):  
Molecular Imaging ◽  
Neuroendocrine Tumors ◽  
Pet Imaging ◽  
Neuroendocrine Neoplasms ◽  
New Agents ◽  
Positron Emission ◽  
Tailored Approach ◽  
Grade 3 ◽  
New Applications ◽  
Chemokine Receptor 4

Neuroendocrine neoplasms make up a heterogeneous group of tumors with inter-patient and intra-patient variabilities. Molecular imaging can help to identify and characterize neuroendocrine tumors (NETs). Furthermore, imaging and treatment with novel theranostics agents offers a new, tailored approach to managing NETs. Recent advances in the management of NETs aim to enhance the effectiveness of targeted treatment with either modifications of known substances or the development of new substances with better targeting features. There have been several attempts to increase the detectability of NET lesions via positron emission tomography (PET) imaging and improvements in pretreatment planning using dosimetry. Especially notable is PET imaging with the radionuclide Copper-64. Increasing interest is also being paid to theranostics of grade 3 and purely differentiated NETs, for example, via targeting of the C-X-C motif chemokine receptor 4 (CXCR4). The aim of this review is to summarize the most relevant recent studies, which present promising new agents in molecular imaging and therapy for NETs, novel combination therapies and new applications of existing molecular imaging modalities in nuclear medicine.

Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors

2019 ◽  
Vol 121 (3) ◽  
pp. 480-485 ◽  
Author(s):  
Angelena Crown ◽  
Flavio G. Rocha ◽  
Preethi Raghu ◽  
Bruce Lin ◽  
Gayle Funk ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Diagnosis And Management ◽  
Pet Ct ◽  
Initial Imaging ◽  
Gallium 68

scholarly journals Use of 68Ga DOTATATE, a new molecular imaging agent, for neuroendocrine tumors

2019 ◽  
Vol 33 (1) ◽  
pp. 51-52
Author(s):  
Raymond Andrew LeBlanc ◽  
Umesh D. Oza ◽  
Ryan Hayden ◽  
Hanna Fanous
Keyword(s):  
Molecular Imaging ◽  
Neuroendocrine Tumors ◽  
Imaging Agent ◽  
Molecular Imaging Agent

NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

Pancreas ◽  
2010 ◽  
Vol 39 (6) ◽  
pp. 784-798 ◽  
Author(s):  
Alexandria T. Phan ◽  
Kjell Öberg ◽  
Junsung Choi ◽  
Lynn H. Harrison ◽  
Manal M. Hassan ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Consensus Guideline ◽  
Diagnosis And Management
Sign in / Sign up

Export Citation Format

Share Document